Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i>-Mutated AML
Astellas Pharma Global Development, Inc.
Alexander E Perl; Giovanni Martinelli; Jorge E Cortes; Andreas Neubauer; Ellin Berman; Stefania Paolini; Pau Montesinos; Maria R Baer; Richard A Larson; Celalettin Ustun; Francesco Fabbiano; Harry P Erba; Antonio Di Stasi; Robert Stuart; Rebecca Olin; Margaret Kasner; Fabio Ciceri; Wen-Chien Chou; Nikolai Podoltsev; Christian Recher; Hisayuki Yokoyama; Naoko Hosono; Sung-Soo Yoon; Je-Hwan Lee; Timothy Pardee; Amir T Fathi; Chaofeng Liu; Nahla Hasabou; Xuan Liu; Erkut Bahceci; Mark J Levis